Patents by Inventor Jerry T. Thompson

Jerry T. Thompson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunotoxin fusion proteins and means for expression thereof
    Patent number: 8987426
    Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: March 24, 2015
    Assignees: The United States of America, as represented by the Secretary, Department of Health & Human Services, Novartis AG
    Inventors: David M. Neville, Jr., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
  • IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF
    Publication number: 20130211049
    Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be ex-pressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
    Type: Application
    Filed: April 10, 2012
    Publication date: August 15, 2013
    Applicants: Office of Technology Transfer
    Inventors: David M. Neville, JR., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
  • Immunotoxin fusion proteins and means for expression thereof
    Patent number: 7696338
    Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein.
    Type: Grant
    Filed: May 18, 2001
    Date of Patent: April 13, 2010
    Assignees: The United States of America as represented by the Department of Health and Human Services, Novartis AG
    Inventors: David M. Neville, Jr., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
  • Immunotoxin fusion proteins and means for expression thereof
    Publication number: 20040127682
    Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
    Type: Application
    Filed: January 13, 2004
    Publication date: July 1, 2004
    Inventors: David M Neville, Jerry T Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
  • Immunotoxins and methods of inducing immune tolerance
    Patent number: 6632928
    Abstract: Provided are novel DT- and ETA-based immunotoxins and a method of treating an immune system disorder not involving T cell proliferation, comprising administering to the animal an immunotoxin comprising a mutant diphtheria toxin moiety linked to an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof under conditions such that the disorder is treated. Thus, the present method can treat graft-versus-host disease.
    Type: Grant
    Filed: December 6, 1999
    Date of Patent: October 14, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David M. Neville, Jerry T. Thompson
  • Novel immunotoxins and methods of inducing immune tolerance
    Publication number: 20030185825
    Abstract: Provided are novel DT- and ETA-based immunotoxins and a method of treating an immune system disorder not involving T cell proliferation, comprising administering to the animal an immunotoxin comprising a mutant diphtheria toxin moiety linked to an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof under conditions such that the disorder is treated. Thus, the present method can treat graft-versus-host disease.
    Type: Application
    Filed: May 9, 2003
    Publication date: October 2, 2003
    Inventors: David M. Neville, Stuart Kenchtle, Judith M. Thomas, Jerry T. Thompson, Huaizhong Hu, Shenglin Ma